Fortress Biotech, Inc. FBIOP
Set alert
As of Nov 2, 3:21 PM ET
- YTD
- +55.74%
- 1 year
- +111.14%
- Open
- 15.05
- Prev close
- 15.10
- Mkt cap
- 62.20M
- Vol
- 16.63K
- Avg vol
- 12.54K
- EPS
- -0.863
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.86
- High
- 15.53
- Forward P/E
- 0.00
- Beta
- 1.75
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 2.34
- Ex-div date
- Jun 13, 2024
- 50-d avg
- 5.83
- 200-d avg
- 10.33
- 1y target
- 0.00
5D chart
Signals (83)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 11:45 AM | 3 hours ago |
| MACD: Buy Signal | Nov 2, 11:45 AM | 3 hours ago |
| SMA: Bullish | Nov 2, 11:40 AM | 3 hours ago |
| MACD: Sell Signal | Nov 2, 11:05 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 10:55 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 10:55 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 10:40 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 10:40 AM | 4 hours ago |
| MACD: Buy Signal | Nov 2, 10:40 AM | 4 hours ago |
| RSI: Overbought | Nov 2, 10:40 AM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 10:25 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 9:55 AM | 5 hours ago |
| RSI: Oversold | Nov 2, 9:55 AM | 5 hours ago |
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:10 PM | 3 days ago |
| RSI: Oversold | Oct 30, 1:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:55 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:55 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 1:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:35 PM | 5 days ago |
| RSI: Oversold | Oct 28, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:10 PM | 5 days ago |
| RSI: Oversold | Oct 28, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:15 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:30 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 6 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:15 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:20 AM | 6 days ago |
| RSI: Oversold | Oct 27, 11:05 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:50 AM | 6 days ago |
News
1 month ago globenewswire.com
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
2 months ago globenewswire.com
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130…
5 months ago seekingalpha.com
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO's recent windfall from the Menkes disease drug sale positions it to easily…
5 months ago globenewswire.com
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
5 months ago globenewswire.com
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205…
6 months ago globenewswire.com
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
7 months ago globenewswire.com
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205…
8 months ago defenseworld.net
Fortress Biotech (NASDAQ:FBIOP) Stock Price Up 22.9% – Here’s What Happened
Fortress Biotech, Inc. (NASDAQ: FBIOP - Get Free Report)'s share price rose 22.9% during mid-day trading on Monday. The stock traded as high as $13.79 and last traded at $13.52. Approximately 205,100…
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
8 months ago globenewswire.com
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium…
8 months ago globenewswire.com
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium…
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
9 months ago globenewswire.com
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium
11 months ago globenewswire.com
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress…
11 months ago seekingalpha.com
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript
Fortress Biotech, Inc. ( FBIO ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jaclyn Jaffe - Senior Director of Corporate Operations Claude Maraoui - Founder, President,…
12 months ago defenseworld.net
Fortress Biotech (NASDAQ:FBIOP) Stock Price Down 1.9% – Time to Sell?
Fortress Biotech, Inc. (NASDAQ: FBIOP - Get Free Report)'s share price was down 1.9% during mid-day trading on Monday. The stock traded as low as $6.80 and last traded at $6.87. Approximately 7,918…
1 year ago globenewswire.com
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago globenewswire.com
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy
1 year ago globenewswire.com
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S.…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
1 year ago globenewswire.com
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
1 year ago globenewswire.com
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value…
1 year ago globenewswire.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™…
-
8 years ago benzinga.com
Stocks Which Set New 52-Week Low Yesterday, October 22nd
Stocks Which Set New 52-Week Low Yesterday, October 22nd
-
8 years ago benzinga.com
Stocks Which Set New 52-Week Low Yesterday, August 2nd
Stocks Which Set New 52-Week Low Yesterday, August 2nd